eli lilly clinical trials retatrutide Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial Eli Lilly weight loss drug

Furthermore, the research supporting systemic (injectable) GHK-Cu for tendon or joint repair in healthy humans is almost non-existent, relying entirely on animal models and anecdotal reports

Metabolic surgery, also referred to as bariatric surgery, has a profound effect on metabolism that greatly accelerates weight loss

The oral GLP-1 currently available: the Wegovy pill The Wegovy pill (oral semaglutide 25 mg) was approved by the FDA in December 2025 and launched in the US in January 2026

Zepbound (tirzepatide) is the same medication as Mounjaro under a different name, approved in Japan specifically for obesity treatment as of April 2025

The trial enrolled 338 adults with obesity or overweight and tracked weight at multiple time points over 48 weeks

10.1111/and.14154 3